National Cord Blood Program Submits Biologics License Application The National Cord Blood Program at New York Blood Center’s Howard P. Milstein National Cord Blood Center has submitted the first publicly-announced Biologics License Application for Cord Blood (Hematopoietic Progenitor Cells, Cord) to the U.S. Food and Drug Administration. [New York Blood Center Press Release]Stemline Therapeutics Receives Orphan Drug Designation for SL-401 for the Treatment of Acute Myeloid Leukemia Stemline Therapeutics, Inc. announced that SL-401 has received Orphan Drug designation from the U.S. Food and Drug Administration for the treatment of acute myeloid leukemia. [Stemline Therapeutics, Inc. Press Release] New Patent Issued for Talon Therapeutics’ Marqibo® Expands Disease Coverage to Include Lymphoma, Leukemia and Myeloma Talon Therapeutics, Inc., announced the issuance of U.S. patent 7,887,836 B2, which covers compositions and methods for treating lymphoma, leukemia and myeloma for Marqibo (vincristine sulfate liposome injection). [Talon Therapeutics, Inc. Press Release] ERYtech Pharma Announces Completion of Enrollment of a Phase II Clinical Trial for GRASPA® in First-Line for Elderly Patients with Acute Lymphoblastic Leukemia ERYtech Pharma announced the early completion of the enrollment and safety follow-up a Phase II clinical trial for GRASPA®. [ERYtech Pharma® Press Release] ERYtech Pharma to Present Promising Results for the Treatment of Sickle Cell Disease ERYtech Pharma will in the near future present their promising results obtained with the GR-ARA1 project for the treatment of sickle cell disease. [ERYtech Pharma® Press Release] $38.4 Million NHMRC Program Grants Extend Cancer and Blood Cell Research Institute research into how cancer develops and blood cell production and function was awarded $38.4 million under the National Health and Medical Research Council’s (NHMRC) program grants scheme. [Walter and Eliza Institute of Medical Research Press Release] OncoVista Innovative Therapies Outlines Business Strategy; “Company Is Moving Full-Speed Ahead,” Says CEO OncoVista Innovative Therapies, Inc., reported in a letter to shareholders that it is moving forward on its business plan to develop targeted, safer and more efficacious cancer treatments with reduced or no toxicity. [OncoVista Innovative Therapies, Inc. Press Release] |